$13.80
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Composition:


active ingredient: 1 tablet contains rauvolfia extract (amounts of alkaloids of rauvolfia) (rauvolfia emetic root extract dry (31-33:1) (extractant: methanol)) 2 mg;


excipients: granulated sugar; corn starch; glucose, monohydrate; calcium stearate; stearic acid; mineral oil; magnesium carbonate light; titanium dioxide (E 171); povidone; talc; silicon dioxide colloidal anhydrous; wax yellow; dye sykovit Green Z2755, containing Quinoline yellow (E 104) and blue patented V (E 131).


Dosage form. Coated tablets.


Basic physical and chemical properties: coated tablets, light green in color, with a biconvex surface. Inclusions are allowed on the surface of tablets. The cross-section shows three layers.


Pharmacotherapeutic group. Antihypertensive agents. Antiadrenergic agents with a central mechanism of action. Rauvolfia alkaloids. ATX code C02A A04.


Pharmacological properties.


Pharmacodynamics. The preparation contains the sum of alkaloids from the roots of rauvolfia serpina or the bark of the roots of rauvolfia emetic of the kutrov family. Alkaloids are represented by reserpine, Serpentine, and aimalin. The total content of alkaloids is not less than 90 %.


Raunatin has a hypotensive effect due to a decrease in the content of biogenic monoamines (norepinephrine, dopamine, serotonin) in the central nervous system (CNS) (Cortico-hypothalamic structures, especially the posterior part of the hypothalamus). Disrupting the processes of mediator deposition in the vesicles of the presynaptic membrane of peripheral adrenergic nerve endings, the vascular wall, and the adrenal medulla, the drug blocks adrenergic transmission, which leads to a gradual decrease in blood pressure. The hypotensive effect of the drug develops more gradually, in contrast to reserpine, but it is not significantly inferior in severity to reserpine. A special feature of the drug is an increase in glomerular filtration in the kidneys, which leads to an increase in renal blood circulation.


The drug also has an antiarrhythmic effect and a calming effect on the central nervous system. The sedative effect of the drug is less pronounced compared to reserpine.


The therapeutic effect of the drug develops gradually up to 10-14 days after the start of its use and persists for 2-3 months.


In some cases, raunatin is better tolerated than reserpine.


Pharmacokinetics. Alkaloids of the drug are well absorbed from the gastrointestinal tract; Cmax in the blood is observed 1-3 hours after administration. Binding to blood proteins is 40-50 %. Half-Life-50-170 hours; metabolized in the intestines and liver, excreted mainly in the feces, as well as in the urine.


Clinical characteristics.


Indications. Mild to moderate arterial hypertension.


Contraindications. Hypersensitivity to rauvolfia alkaloids; hypotension, heart failure, organic heart damage, bradycardia, aortic malformations, severe cerebral atherosclerosis, depression, epilepsy, Parkinsonism, peptic ulcer of the stomach and duodenum in the acute stage, ulcerative colitis, nephrosclerosis, bronchial asthma, pheochromocytoma, electroconvulsive therapy (the drug should be discontinued at least 7 days before electroconvulsive therapy).


Interactions with other drugs and other types of interactions. When used concomitantly with MAO inhibitors, agitation and arterial hypertension may develop. The antihypertensive effect of raunatin is enhanced when used with other antihypertensive agents (thiazide diuretics, beta-blockers, ACE inhibitors, calcium ion antagonists). Increases the depressing effect on the central nervous system (CNS) of alcohol, barbiturates, antidepressants. Digitalis preparations or quinidine, when used concomitantly with raunatin, can cause arrhythmia. Reduces the effectiveness of antiparkinsonian agents and sympathomimetics.


Application features. Treatment with the drug should be carried out under the supervision of a doctor. In patients with angina pectoris, pain in the heart area may increase.


Before planned surgical interventions, the drug should be discontinued a few days before surgery. If emergency surgery is necessary under general anesthesia in patients taking raunatin, premedication with atropine is required.


Do not use the drug before electro-pulse therapy.


Since rauvolfia alkaloids increase motility and secretion in the digestive tract, caution should be exercised when using the drug in patients with anamnestic data on peptic ulcer disease.


Caution should also be exercised when using the drug in weakened patients and elderly patients; in the presence of renal failure, cholelithiasis, arrhythmia, patients who have recently suffered a myocardial infarction.


If the patient is found to be intolerant to certain sugars, you should consult your doctor before taking this medicine.


Use during pregnancy or lactation. The use of the drug during pregnancy or lactation is contraindicated, since the alkaloid reserpine penetrates through the placenta and into breast milk. If it is necessary to use the drug for the duration of treatment, breast-feeding should be discontinued.


Ability to influence the reaction rate when driving vehicles or other mechanisms. The drug may impair the patient's ability to respond quickly, especially at the beginning of treatment, as a result of which, during the course of treatment with the drug, patients should avoid potentially dangerous activities that require increased attention and speed of psychomotor reactions.


Dosage and administration. Raunatin should be administered orally to adults after meals.


On Day 1, the initial dose is usually 1 tablet per night, on Day 2-1 tablet 2 times a day, on Day 3 – 1 tablet 3 times a day, then bring the total dose to 4-6 tablets per day. After achieving a stable therapeutic effect (usually after 10-14 days), the dose of the drug should be gradually reduced to 1-2 tablets per day. The course of treatment is 3-4 weeks, but in some cases, according to indications, the drug should be taken for a long time in a maintenance dose (1 tablet per day).


Children. There are no data on the use of the drug in children.


Overdose.


Symptoms: sweating, general weakness, and severe hypotension. In severe cases, after a short period of euphoria, drowsiness, inactivity, severe depression (which can lead to suicide), severe Parkinsonism, loss of consciousness, coma, convulsions, respiratory depression, hypothermia develop.


Treatment: gastric lavage, taking activated charcoal. Forced diuresis is indicated. With a pronounced decrease in blood pressure, with a collapse, put the patient down and lift his legs; if necessary, intravenous administration of rheopolyglucin or mezaton with the addition of angiotensinamide or a 2% solution of norepinephrine hydrotartrate is indicated. Adrenomimetic agents should be prescribed with great caution because of the risk of developing pulmonary edema. Subcutaneously inject a 10% solution of caffeine-sodium benzoate. The presence of severe respiratory depression or its delay requires suction of mucus from the respiratory tract, intubation and artificial ventilation, oxygen therapy.


There are no specific antidotes for poisoning with raunatin and other rauvolfia drugs.


Adverse reactions. The drug is usually well tolerated. Sometimes possible:


From the cardiovascular system: edema, hot flashes, bradycardia, in patients with angina pectoris, pain in the heart may increase; with prolonged use, the frequency of angina attacks may increase.


From the nervous system: headache, drowsiness, sweating, depression, general weakness; with prolonged use – the appearance of nightmares, the development of Parkinsonism symptoms.


From the side of the visual organs: miosis.


From the digestive system: nausea, vomiting, diarrhea, abdominal pain, increased or decreased appetite, drooling, dry mouth, increased gastric juice secretion.


From the side of the hepatobiliary system: with prolonged use in high doses, liver function may be impaired.


From the genitourinary system: dysuria, impotence.


From the endocrine system and metabolism: decreased libido, sodium retention, increased prolactin secretion, galactorrhea, gynecomastia, breast swelling, weight gain.


Allergic reactions: skin rashes, itching, dryness of the mucous membranes, swelling of the nasal mucosa.


From the hematopoietic system: thrombocytopenic purpura.


Side effects disappear when the dose is reduced or after a short (1-3 days) break in taking the drug.

Tags: Raunatin